HBM Holdings is gaining attention after Harbour BioMed partnered with China National Pharmaceutical Group to establish the Sinopharm Harbour BioMed Innovation Consortium, focusing on biologic drug research and development. Although HBM’s share price recently fell by 1.74%, it experienced a notable 23.26% increase over the past month, suggesting strong long-term momentum despite recent volatility.
Currently trading at a Price-to-Earnings (P/E) ratio of 15x, HBM appears undervalued compared to the biotech industry average of 31.4x. However, cash flow estimates suggest the stock is overvalued at its current price of HK$12.40, with a fair value closer to HK$9.22 according to a discounted cash flow model. Investors are advised to consider both earnings and cash flow metrics before making investment decisions, especially in light of potential risks affecting revenue growth and valuation estimates.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-undervalued-as-its-sinopharm-biolog
